Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.48 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022986 | 1.00 | AKT1 (0.50) | AKT1AKT2AKT1S1AKT3 | |
| SCHEMBL191679 | 1.00 | AKT1 (0.50) | AKT1AKT2AKT1S1AKT3 | |
| SCHEMBL675548 | 1.00 | AKT1 (0.50) | AKT1AKT2AKT1S1AKT3 | |
| SCHEMBL191678 | 1.00 | AKT1 (0.50) | AKT1AKT2AKT1S1AKT3 | |
| SCHEMBL190622 | 0.90 | AKT1 (0.54) | AKT1AKT2AKT3 | |
| SCHEMBL193217 | 0.90 | AKT1 (0.54) | AKT1AKT2AKT3 | |
| SCHEMBL190621 | 0.90 | AKT1 (0.54) | AKT1AKT2AKT3 | |
| SCHEMBL191806 | 0.86 | AKT1 (0.65) | AKT1AKT2AKT1S1AKT3 | |
| SCHEMBL676511 | 0.85 | AKT1 (0.57) | AKT1AKT2AKT3 | |
| SCHEMBL676512 | 0.85 | AKT1 (0.57) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT1S1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.